RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Michael A. Chapman(Toronto Metropolitan University), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Mahnaz Abbasian(University College London), Claire Roddie(Cancer Institute (WIA)), Jonathan Sive(University College London Hospitals NHS Foundation Trust), Nicholas Counsell(University College London), Mickey Koh(St George's Hospital), Gordon Cook(University of Leeds), Javier Herrero(London Cancer), Laura Clifton‐Hadley(Cancer Research UK), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Toyin Adedayo(Cancer Research UK), Mark Cook(Université Paris Cité), Matthew Streetly(King's College - North Carolina), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Nivette Braganza(Cancer Research UK), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Josephine Crowe(Royal United Hospital), Jonathan J. Keats(Translational Genomics Research Institute), John C. Ambrose(Jackson Laboratory), Paul Smith(Cancer Research UK), Stephen Schey(University College Hospital), Andres Virchis(The Royal Free Hospital), Michael F. Quinn(University of Ulster), Charles Crawley(Addenbrooke's Hospital), Jamie Cavenagh(St Bartholomew's Hospital), Pieter Sonneveld(Erasmus MC Cancer Institute), Fenella Willis(St George's Hospital), Heather Oakervee(Barts Health NHS Trust)
Blood
September 4, 2018
Cited by 20


Related Papers